IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from
Abdul Hamid Bazarbachi1,2, Hervé Avet-Loiseau3, Raphael Szalat4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Abstract:
Immunoglobulin M (IgM) multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenström macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole-genome and transcriptome sequencing to identify differentiating characteristics from non-IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics, including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH recombination-induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class switching, these data favor a pre-germinal center origin. Finally, we found elevated expression of clinically relevant targets, including CD20 and Bruton tyrosine kinase, as well as high BCL2/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.
Insights
Immunoglobulin M (IgM) multiple myeloma (MM) has unique genomic and transcriptomic features differentiating it from other conditions. These findings suggest potential new targeted therapies for this rare plasma cell disorder.
Area of Science:
- Hematology
- Oncology
- Genomics
- Transcriptomics
Background:
- Immunoglobulin M (IgM) multiple myeloma (MM) is a rare subtype of multiple myeloma.
- Distinguishing IgM MM from other IgM gammopathies like Waldenström macroglobulinemia (WM) is crucial for accurate diagnosis and treatment planning.
- Limited characterization of IgM MM's unique molecular features hinders optimal patient management.
Purpose of the Study:
- To investigate the genomic and transcriptomic profiles of IgM multiple myeloma (MM) samples.
- To identify key molecular characteristics that differentiate IgM MM from non-IgM MM and Waldenström macroglobulinemia (WM).
- To explore potential therapeutic targets in IgM MM based on molecular signatures.
Main Methods:
- Whole-genome sequencing and transcriptome sequencing were performed on IgM-MM patient samples.
- Comparative analysis of genomic structural variants and gene expression profiles.
- Identification of specific translocations, chromosomal deletions, and molecular signatures.
Main Results:
- IgM-MM shares common structural variants and gene expression with typical MM but exhibits distinct features.
- Key differentiating characteristics include t(11;14) translocation, deletions on chromosomes 6 and 13, and unique molecular/transcription-factor signatures.
- IgM-MM translocations suggest a pre-germinal center origin due to VHDHJH recombination and lack of class switching.
- Elevated expression of CD20, Bruton tyrosine kinase, and a high BCL2/BCL2L1 ratio were observed, indicating potential therapeutic avenues.
Conclusions:
- IgM-MM possesses a distinct molecular profile compared to non-IgM MM and WM.
- The identified genomic and transcriptomic signatures, including pre-germinal center origin markers, aid in differential diagnosis.
- Elevated expression of CD20, Bruton tyrosine kinase, and the BCL2/BCL2L1 ratio highlight promising targets for novel therapeutic strategies in IgM MM.
